ES3057414T3 - Interleukin 5 binding protein dosage regimen - Google Patents

Interleukin 5 binding protein dosage regimen

Info

Publication number
ES3057414T3
ES3057414T3 ES21844228T ES21844228T ES3057414T3 ES 3057414 T3 ES3057414 T3 ES 3057414T3 ES 21844228 T ES21844228 T ES 21844228T ES 21844228 T ES21844228 T ES 21844228T ES 3057414 T3 ES3057414 T3 ES 3057414T3
Authority
ES
Spain
Prior art keywords
asthma
approximately
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21844228T
Other languages
English (en)
Spanish (es)
Inventor
Daren J Austin
Nicholas P Bird
Myrna A Monck
Isabelle J Pouliquen
Melissa A Shuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority claimed from PCT/EP2021/086689 external-priority patent/WO2022136209A1/en
Application granted granted Critical
Publication of ES3057414T3 publication Critical patent/ES3057414T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0053—Syringes, pipettes or oral dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
ES21844228T 2020-12-22 2021-12-20 Interleukin 5 binding protein dosage regimen Active ES3057414T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063128922P 2020-12-22 2020-12-22
US202163192854P 2021-05-25 2021-05-25
US202163220182P 2021-07-09 2021-07-09
US202163285513P 2021-12-03 2021-12-03
PCT/EP2021/086689 WO2022136209A1 (en) 2020-12-22 2021-12-20 Interleukin 5 binding protein dosage regimen

Publications (1)

Publication Number Publication Date
ES3057414T3 true ES3057414T3 (en) 2026-03-02

Family

ID=86732980

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21844228T Active ES3057414T3 (en) 2020-12-22 2021-12-20 Interleukin 5 binding protein dosage regimen

Country Status (5)

Country Link
US (1) US20240043524A1 (https=)
EP (2) EP4644416A3 (https=)
JP (1) JP2024500912A (https=)
CA (1) CA3199805A1 (https=)
ES (1) ES3057414T3 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026078117A1 (en) * 2024-10-11 2026-04-16 Glaxosmithkline Intellectual Property Development Limited Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699293B8 (en) * 2011-04-20 2022-07-20 Amgen Inc. Autoinjector apparatus
CA2921927A1 (en) * 2013-08-19 2015-02-26 Dr. Reddy's Laboratories, Ltd. Selectable single dose auto-injector and methods of making and using same
TWI799417B (zh) * 2017-05-26 2023-04-21 英商葛蘭素史克智慧財產發展有限公司 生物製藥組成物及相關方法
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
US11613571B2 (en) * 2018-05-23 2023-03-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants

Also Published As

Publication number Publication date
EP4267184B1 (en) 2025-11-26
EP4644416A3 (en) 2026-01-21
EP4644416A2 (en) 2025-11-05
JP2024500912A (ja) 2024-01-10
EP4267184A1 (en) 2023-11-01
CA3199805A1 (en) 2022-06-30
US20240043524A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
ES3053874T3 (en) Biopharmaceutical compositions
BR112019021482A2 (pt) Tratamento da asma com anticorpo anti-tslp
JP6596014B2 (ja) 爪および頭皮乾癬の治療方法
EP2777710A1 (en) Methods for administering anti-IL-5 antibodies
JP2019529560A (ja) Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
TW202317622A (zh) 以ｓｔ２拮抗劑治療慢性阻塞性肺病的方法
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
ES3057414T3 (en) Interleukin 5 binding protein dosage regimen
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
US12552869B2 (en) CSF-1R antibodies for the treatment of chronic graft versus host disease
EP3634467A1 (en) Biopharmaceutical compositions and methods for pediatric patients
CN114786775A (zh) 通过施用il-33拮抗剂治疗copd的方法
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
CN119894931A (zh) 用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体
WO2022136209A1 (en) Interleukin 5 binding protein dosage regimen
CN116635417A (zh) 白介素5结合蛋白给药方案
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2026047072A1 (en) Medical use
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법
CN121399161A (zh) 每两个月一次施用fviii模拟双特异性抗体的方法
EA052089B1 (ru) Антитела для лечения хронического заболевания "трансплантат против хозяина"
NZ619873B2 (en) Methods and compositions for treating asthma using anti-il-13 antibodies